Replies to post #650382 on NorthWest Biotherapeutics Inc (NWBO)

[newman2021]

ex, any spin on the dcvaxl plus pclyc combo k-y curves?? you know the expected priority completion is January 2024? 50% alive >8 yrs must be very impressive to the regulators and the NICE pricings, don't you think so?? fudster ba******s.

[Dr Bala]

Fudster-extraordinaire has a background of besmirching posts of this therapy and has no understanding of the JAMA data. Look at Fig. 2 of the JAMA data and try to get a modicum of understanding. Spouting off on an anonymous board is the fudster's mode of operation.

[hoffmann6383]

People can question the trial design all they want but we already have approval from the MHRA, the FDA and other such regulators. It's a pointless narrative the hedge fund social media continues to hammer away at to scare investors that don't realize this is a non issue.



External controls are the norm these days. Some doctors throw ethics out of the window and want thousands more GBM patients to die early deaths because the thousands before them wasn't enough. Fortunately, the regulatory bodies don't share this draconian view.

$NWBO

External controls in oncology indications are the norm at the FDA. Period.

"Pivotal trials supporting oncology approvals were much more likely to use a historical control than nononcology approvals (13 [72.2%] vs 8 [14.0%]; P < .001)..."https://t.co/CPyohBztFI pic.twitter.com/ap41RUpvVb

— Hoffmann (@hoffmann6383) April 21, 2023

[flipper44]

You are encouraging the Cheng/Reardon lie (against NWBO) and obfuscating a massive deception by them — aka, trying to persuade/confuse the audience that time from surgery is the same thing as time from randomization, and thereby deceiving readers by trying to make results look bad.